Scarica l'app Stockscreener
20.21
5.96%
-1.28
Dopo l'orario di chiusura:
20.30
0.09
+0.45%
Precedente Chiudi:
$21.49
Aprire:
$21.5
Volume 24 ore:
1.30M
Relative Volume:
1.48
Capitalizzazione di mercato:
$1.50B
Reddito:
$97.36M
Utile/perdita netta:
$-172.42M
Rapporto P/E:
-8.7931
EPS:
-2.2984
Flusso di cassa netto:
$-188.84M
1 W Prestazione:
+3.96%
1M Prestazione:
+25.53%
6M Prestazione:
+67.16%
1 anno Prestazione:
+142.91%
Intervallo 1D:
$19.77
$21.57
Intervallo di 1 settimana:
$19.04
$21.76
Portata 52W:
$6.92
$21.76
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
20.21 | 1.47B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor Inc (XNCR) Income Statement - TradingKey
Xencor Inc (XNCR) Cash Flow - TradingKey
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xencor Inc (XNCR) Balance Sheet - TradingKey
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XNCR|Xencor Inc|Price:19.830|Chg%:+0.390 - TradingKey
ETFs Investing in Xencor, Inc. Stocks - TradingView
Xencor, Inc. Revenue Breakdown – DUS:XE9 - TradingView
Xencor Inc (XNCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Stock Price Down 6.7%Should You Sell? - MarketBeat
(XNCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Xencor (NASDAQ:XNCR) Hits A High: Can Momentum Last? - Kalkine Media
Xencor stock hits 52-week high at 18.83 USD - Investing.com India
Xencor (NASDAQ:XNCR) Sets New 52-Week HighShould You Buy? - MarketBeat
Xencor stock hits 52-week high at 18.83 USD By Investing.com - Investing.com South Africa
Xencor (NASDAQ:XNCR) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Xencor Shares Kidney Cancer Trial Results at ESMO - t.co
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - BioSpace
Xencor shows strong pipeline progress with prom... - Pluang
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data - Seeking Alpha
Xencor (XNCR) Shares Jump 17% Following ESMO 2026 Announcement - GuruFocus
Xencor (NASDAQ:XNCR) Stock Price Up 7.9%What's Next? - MarketBeat
Xencor’s XmAb819 data to be presented at ESMO congress By Investing.com - Investing.com South Africa
Xencor’s XmAb819 data to be presented at ESMO congress - Investing.com
Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026 - Bitget
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus - The National Law Review
Xencor: Bullish On Their Increasingly In-House Pipeline (NASDAQ:XNCR) - Seeking Alpha
Xencor (NASDAQ:XNCR) Shares Down 6.6%Should You Sell? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor Inc. (XNCR) Faces Pressure as Shares Slide Toward Key SupportQuality Factor - dars.gov.et
Form 4 Xencor Inc For: 8 July By Investing.com - Investing.com Nigeria
Ellen Feigal at Xencor (XNCR) receives RSUs and options equity awards - Stock Titan
Xencor (XNCR) awards RSUs and stock options to director Gorman - Stock Titan
Xencor (XNCR) director Kurt Gustafson granted RSUs and stock options - Stock Titan
[Form 4] Xencor Inc Insider Trading Activity - Stock Titan
Xencor (XNCR) director granted RSUs and stock options in equity award - Stock Titan
Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20 - Stock Titan
Xencor (NASDAQ: XNCR) awards director stock grants vesting within a year - Stock Titan
Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant - Stock Titan
Frontier tech research, news & data - MLQ.ai
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $27 - Moomoo
XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities - GuruFocus
XNCRXencor Inc Revenue Breakdown - Finviz
Xencor (XNCR) Declines 4.5% as Selling Pressure Builds Near SupportTurnaround Stocks - dars.gov.et
Enterprise value to revenue forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to earnings forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Enterprise value to EBIT forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):